A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2016
At a glance
- Drugs Rituximab (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 03 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 29 Sep 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
- 28 Feb 2014 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.